Tau Protein News and Research

RSS

Tau proteins are microtubule-associated proteins found in neurons in the brain.

Major trial to test multiple drugs for progressive supranuclear palsy

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start.

3 Sep 2024

American football head impacts tied to increased brain damage and cognitive decline

Repetitive head impacts in former American football players are linked to increased perivascular space volume, which correlates with cognitive decline and neurodegeneration. The study suggests that the force of head impacts may be more critical than frequency, with potential protective effects from β-blocker use.

1 Sep 2024

Tau protein shows unexpected benefits in mitigating brain damage

A study by researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital, reveals that the protein Tau – a key player implicated in several neurodegenerative conditions including Alzheimer's disease – also plays a positive role in the brain.

30 Aug 2024

Breakthrough compound targets appetite and tau protein in obesity and Alzheimer's

Scientists on the team of Dr Lenka Maletínská have developed a promising new compound derived from one of the peptides naturally occurring in the brain.

21 Aug 2024

New compound shows promise in Alzheimer’s preclinical models

A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego, has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.

21 Aug 2024

Emory researchers offer a new perspective on the mechanism behind Alzheimer's disease

New findings out of Emory University are challenging existing theories about the origins of Alzheimer's, the leading cause of dementia in the elderly worldwide.

12 Aug 2024

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Researchers highlighted the complexities of using amyloid immunotherapy for early Alzheimer's disease, discussing its clinical benefits, challenges, and broader health implications. Despite some positive results, concerns over adverse effects, trial biases, and cost hinder widespread adoption.

7 Aug 2024

New lab technique captures aging effects in Alzheimer's disease development

Researchers at Washington University School of Medicine in St. Louis have developed a way to capture the effects of aging in the development of Alzheimer's disease.

1 Aug 2024

New blood test achieves 90% accuracy in diagnosing Alzheimer’s disease, outperforms doctors

Researchers in Sweden developed a combined blood test with up to 90% accuracy for diagnosing Alzheimer's disease, surpassing the diagnostic rates of primary care doctors and specialists.

29 Jul 2024

Hormone modulating therapy may lower dementia risk in breast cancer survivors

Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new study published today in JAMA Network Open.

16 Jul 2024

Experts produce consensus statement on sex and gender disparities in resilience to Alzheimer's

An international panel of experts led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, under the umbrella of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment, has produced a consensus statement on sex and gender disparities in resilience to Alzheimer's disease and call for incorporating these differences in future research.

5 Jul 2024

Nonhuman primate model reveals early-stage Alzheimer’s disease progression

Research in nonhuman primates is opening the possibility of testing treatments for the early stages of Alzheimer’s and similar diseases, before extensive brain cell death and dementia set in.

26 Jun 2024

New study in rhesus macaques offers early intervention window for Alzheimer's

Research in nonhuman primates is opening the possibility of testing treatments for the early stages of Alzheimer's and similar diseases, before extensive brain cell death and dementia set in.

24 Jun 2024

Blood test identifies specific pathologies in frontotemporal dementia, ALS, and PSP

In a study with 991 adults, scientists at DZNE show that the most common forms of frontotemporal dementia (FTD) as well as the neurological diseases amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP) can be recognized by blood testing.

18 Jun 2024

Existing cancer drug shows promise in blocking alpha-synuclein spread in Parkinson's mice

In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson's disease-causing alpha-synuclein.

18 Jun 2024

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Review demonstrates curcumin's neuroprotective effects in neurodegenerative diseases, enhancing its potential through innovative nanoparticle formulations. This advancement could significantly improve treatments for diseases like Parkinson's, Alzheimer's, and Multiple Sclerosis.

6 Jun 2024

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.

28 May 2024

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine ("Insilico") and ETH Zurich reveals the broad potential of TNIK as a therapeutic target for some of the most pervasive aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer's.

28 May 2024

Understanding the role of oxidative stress in Alzheimer's disease pathogenesis

The number of people suffering from Alzheimer's disease (AD) is expected to reach 100 million by 2050, but there is still no effective therapy.

21 May 2024

State-of-the art imaging reveals how lipid metabolism is changed in Alzheimer's disease

Alzheimer's disease causes significant problems with memory, thinking and behavior and is the most common form of dementia, affecting more than 50 million people around the world each year.

23 Apr 2024